News

Law

Asset Management

Investment Banking

Wealth

Hedge Funds

People

Newsletters

Events

Lists

Advisers in line for £112m GlaxoSmithKline merger fees

Advisers to Glaxo Wellcome and SmithKline Beecham can relax in the knowledge they will receive their fees, as the US Federal Trade Commission agrees to clear the $68bn (€77.5bn) pharmaceuticals merger.

The Federal Trade Commission clearance marks the final regulatory hurdle to the merger, which is due to complete on December 27.

WSJ Logo